Literature DB >> 26571205

Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.

Katherine E Olson1, Howard E Gendelman2.   

Abstract

While immune control is associated with nigrostriatal neuroprotection for Parkinson's disease, direct cause and effect relationships have not yet been realized, and modulating the immune system for therapeutic gain has been openly debated. Here, we review how innate and adaptive immunity affect disease pathobiology, and how each could be harnessed for treatment. The overarching idea is to employ immunopharmacologics as neuroprotective strategies for disease. The aim of the current work is to review disease-modifying treatments that are currently being developed as neuroprotective strategies for PD in experimental animal models and for human disease translation. The long-term goal of this research is to effectively harness the immune system to slow or prevent PD pathobiology.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26571205      PMCID: PMC4716884          DOI: 10.1016/j.coph.2015.10.006

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  79 in total

Review 1.  Regulatory T cells in the central nervous system.

Authors:  Daniel E Lowther; David A Hafler
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

2.  Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum.

Authors:  Y He; S Appel; W Le
Journal:  Brain Res       Date:  2001-08-03       Impact factor: 3.252

3.  MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease.

Authors:  I Kurkowska-Jastrzebska; A Wrońska; M Kohutnicka; A Członkowski; A Członkowska
Journal:  Acta Neurobiol Exp (Wars)       Date:  1999       Impact factor: 1.579

4.  Amplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in mice.

Authors:  Shin-Young Na; Eva Mracsko; Arthur Liesz; Thomas Hünig; Roland Veltkamp
Journal:  Stroke       Date:  2014-11-06       Impact factor: 7.914

5.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

Review 6.  Novel anti-inflammatory and neuroprotective agents for Parkinson's disease.

Authors:  Li Lu; Fengqiao Li; Xiaomin Wang
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

7.  A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results.

Authors: 
Journal:  Clin Neuropharmacol       Date:  2008 May-Jun       Impact factor: 1.592

Review 8.  Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?

Authors:  Anna R Carta; Augusta Pisanu
Journal:  Neurotox Res       Date:  2012-08-07       Impact factor: 3.911

9.  Bee Venom Phospholipase A2, a Novel Foxp3+ Regulatory T Cell Inducer, Protects Dopaminergic Neurons by Modulating Neuroinflammatory Responses in a Mouse Model of Parkinson's Disease.

Authors:  Eun Sook Chung; Gihyun Lee; Chanju Lee; Minsook Ye; Hwan-suck Chung; Hyunseong Kim; Sung-joo S Bae; Deok-Sang Hwang; Hyunsu Bae
Journal:  J Immunol       Date:  2015-10-09       Impact factor: 5.422

Review 10.  Apocynin, a low molecular oral treatment for neurodegenerative disease.

Authors:  Bert A 't Hart; Sjef Copray; Ingrid Philippens
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

View more
  25 in total

1.  The Second Insubria Autumn School on Neuroimmune Pharmacology: Repurposing Established Drugs for Novel Indications.

Authors:  Marco Cosentino; Franca Marino
Journal:  J Neuroimmune Pharmacol       Date:  2015-12-16       Impact factor: 4.147

Review 2.  Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease.

Authors:  Katherine E Olson; Aditya N Bade; Charles R Schutt; Jingdong Dong; Scott J Shandler; Michael D Boska; R Lee Mosley; Howard E Gendelman; Yutong Liu
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

3.  Isorhynchophylline Attenuates MPP+-Induced Apoptosis Through Endoplasmic Reticulum Stress- and Mitochondria-Dependent Pathways in PC12 Cells: Involvement of Antioxidant Activity.

Authors:  Xiao-Ming Li; Xiao-Jie Zhang; Miao-Xian Dong
Journal:  Neuromolecular Med       Date:  2017-08-18       Impact factor: 3.843

4.  Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer's disease mice.

Authors:  Tomomi Kiyota; Jatin Machhi; Yaman Lu; Bhagyalaxmi Dyavarshetty; Maryam Nemati; Izumi Yokoyama; R L Mosley; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2018-03-17       Impact factor: 3.478

5.  Interleukin 6 and complement serum level study in Parkinson's disease.

Authors:  Branislav Veselý; Michal Dufek; Vojtech Thon; Miroslav Brozman; Silvia Királová; Tatiana Halászová; Eva Koriťáková; Ivan Rektor
Journal:  J Neural Transm (Vienna)       Date:  2018-02-12       Impact factor: 3.575

6.  Tinospora cordifolia Suppresses Neuroinflammation in Parkinsonian Mouse Model.

Authors:  Hareram Birla; Sachchida Nand Rai; Saumitra Sen Singh; Walia Zahra; Arun Rawat; Neeraj Tiwari; Rakesh K Singh; Abhishek Pathak; Surya Pratap Singh
Journal:  Neuromolecular Med       Date:  2019-01-14       Impact factor: 3.843

Review 7.  The dopamine transporter: An unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson's Disease.

Authors:  Phillip Mackie; Joe Lebowitz; Leila Saadatpour; Emily Nickoloff; Peter Gaskill; Habibeh Khoshbouei
Journal:  Brain Behav Immun       Date:  2018-03-15       Impact factor: 7.217

8.  Granulocyte-macrophage colony-stimulating factor mRNA and Neuroprotective Immunity in Parkinson's disease.

Authors:  Katherine E Olson; Krista L Namminga; Yaman Lu; Mackenzie J Thurston; Aaron D Schwab; Seymour de Picciotto; Sze-Wah Tse; William Walker; Jared Iacovelli; Clayton Small; Brian T Wipke; R Lee Mosley; Eric Huang; Howard E Gendelman
Journal:  Biomaterials       Date:  2021-03-31       Impact factor: 12.479

9.  Mucuna pruriens Protects against MPTP Intoxicated Neuroinflammation in Parkinson's Disease through NF-κB/pAKT Signaling Pathways.

Authors:  Sachchida N Rai; Hareram Birla; Saumitra S Singh; Walia Zahra; Ravishankar R Patil; Jyoti P Jadhav; Mallikarjuna R Gedda; Surya P Singh
Journal:  Front Aging Neurosci       Date:  2017-12-19       Impact factor: 5.750

10.  Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice.

Authors:  Mantia Karampetsou; Mustafa T Ardah; Maria Semitekolou; Alexia Polissidis; Martina Samiotaki; Maria Kalomoiri; Nour Majbour; Georgina Xanthou; Omar M A El-Agnaf; Kostas Vekrellis
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.